Technology

Transformative Cell Therapy Technology

Artificial Membrane-Binding Proteins (AMBPs) are fusion proteins comprising a supercharged Anchor domain and a therapeutic Functional domain.

The Anchor allows the AMBP to bind electrostatically to virtually any membrane through a simple coating procedure, providing additional function to the cell without the need for genetic modification.

The Functional domain is then presented at the external surface of the cell at high concentrations. The Functional domain may be a peptide, protein, or enzyme. The precise targeting of the Functional domain reduces the risk of toxicity associated with systemic delivery, and the effects have a tuneable time-limited effect, potentially reducing off-target effects associated with genetic engineering approaches.

Our current generation of AMBPs are designed to enhance therapeutic immune cells targeting solid tumours.

Cell Therapy Applications for Solid Tumours

There remains a significant unmet need for cancer patients despite development of new approaches. The first cell therapies for cancer based on CAR-T cells have been approved but have significant side effects and are limited to a few indications. Other cell types are also being pursued as potential therapies for cancer, including NK cells. No cell therapies are approved yet for solid tumours; the major cause of death due to cancer worldwide

CytoSeek's mission is to leverage its AMBP platform technology to deliver transformative cell therapies for treating patients wih solid tumour cancers.